Renowned cancer researcher Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for ... more>>
Traditionally, oncology drug developers have regarded the phase I clinical trial as having a utility limited to the assessment of safety, tolerability ... more>>
General introductory presentation to Medelis' oncology CRO services in the U.S., Europe and Asia. more>>
Patient safety has always been the industry’s focus during clinical trials. However, a recent spate of well-publicized patient safety issues have ... more>>
A Q&A with Dr. Mike McGarry, VP of Preclinical Study at Medelis. He describes a nuanced preclinical study process that can help a biotech Chief ... more>>
Renowned oncology researcher Dr. Dan Von Hoff discusses the complete phase Ib, a clinical trial approach that helps oncology biotech and pharma ... more>>